US CHPA proposal "will not protect children"

19 October 2008

The proposal by the US Consumer Healthcare Products Association to voluntarily change the labeling of cough and cold remedies to instruct parents not to give them to children aged under four years has been attacked as "a political compromise, not a solution based on scientific evidence," by the consumer group Public Citizen. The move by the representative body of over-the-counter drugs was taken in response to a call by a number of organizations, to prohibit the use of such treatments for children aged 12 or less.

Public Citizen is a campaigning group which among others, supports a ban on drug industry advertising and has lobbied in favor of price controls on Medicare-supplied medicines (Marketletters passim). The group also opposes a "behind-the-counter" approach, which allows a consumer to speak to a pharmacist and obtain advice and purchase certain drugs without a physician's prescription (Marketletter November 26, 2007).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight